Let’s make a deal, Revvity (NYSE: RVTY) to acquire ACD/Labs

Revvity, Inc. (NYSE: RVTY) has entered into a definitive agreement to acquire ACD/Labs, a provider of scientific software solutions for pharmaceutical and material sciences markets, according to a company statement.

The acquisition will integrate ACD/Labs’ analytical characterization and molecular design tools into Revvity’s Signals software platform. ACD/Labs offers solutions including the Spectrus Platform for spectral analysis, the Percepta Platform for AI-driven molecular property prediction, and other specialized applications for pharmaceutical chemistry and manufacturing.

The transaction is expected to close in the fourth quarter of 2025. Financial terms of the deal were not disclosed in the announcement.

“By integrating ACD/Labs’ technologies into the Revvity Signals platform, we’re giving our customers across pharmaceuticals and material sciences a truly unified SaaS environment,” said Kevin Willoe, president of Revvity Signals Software.

ACD/Labs has operated in the scientific software sector for over 30 years, providing tools that support analytical and process chemistry within pharmaceutical and chemical research and development workflows. The company’s solutions help scientists identify and characterize molecules, monitor quality, and support production processes.